Virtu Financial LLC acquired a new stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,372 shares of the biopharmaceutical company’s stock, valued at approximately $342,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at $156,000. Aperio Group LLC bought a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at $254,000. Verity Asset Management Inc. bought a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at $306,000. Canada Pension Plan Investment Board bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at $330,000. Finally, Jane Street Group LLC bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at $372,000. 87.19% of the stock is owned by institutional investors and hedge funds.
Shares of Ultragenyx Pharmaceutical Inc (RARE) opened at $54.03 on Monday. The stock has a market capitalization of $2,668.79, a price-to-earnings ratio of -7.57 and a beta of 1.93. Ultragenyx Pharmaceutical Inc has a 12-month low of $41.67 and a 12-month high of $88.95.
Several equities analysts have weighed in on the company. BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Jefferies Group raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and increased their price objective for the company from $58.00 to $72.00 in a report on Monday, December 4th. Barclays increased their price objective on Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Tuesday, December 5th. Finally, Raymond James Financial restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $68.94.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.